Revolution Medicines is one of the big share price losers following the European Society of Medical Oncology (ESMO) meeting, its stock declining more than 30% this week after the firm presented new data on the multi-RAS-targeting contender RMC-6236.
That left the NASDAQ-listed biotech’s shares at just under $20 a share, but most sellside analysts think investor reaction is...